CancerDrs

Cervical Cancer clinical trials in Wisconsin

20 actively recruiting cervical cancer trials at 51 sites across Wisconsin.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Wisconsin:
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Northwest Wisconsin Cancer Center — Ashland, Wisconsin
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Wisconsin:
  • Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
  • Aurora Saint Luke's South Shore — Cudahy, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Aurora Health Care Germantown Health Center — Germantown, Wisconsin
  • Aurora Cancer Care-Grafton — Grafton, Wisconsin
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Wisconsin:
  • Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
  • Froedtert and MCW Moorland Reserve Health Center — New Berlin, Wisconsin
  • Drexel Town Square Health Center — Oak Creek, Wisconsin
  • Froedtert West Bend Hospital/Kraemer Cancer Center — West Bend, Wisconsin
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Wisconsin:
  • Medical College of Wisconsin - Froedtert Hospital Cancer Center — Milwaukee, Wisconsin
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Northwest Wisconsin Cancer Center — Ashland, Wisconsin
  • Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
  • Aurora Saint Luke's South Shore — Cudahy, Wisconsin
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Wisconsin:
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Wisconsin:
  • Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • HSHS Sacred Heart Hospital — Eau Claire, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Wisconsin:
  • Langlade Hospital and Cancer Center — Antigo, Wisconsin
  • Northwest Wisconsin Cancer Center — Ashland, Wisconsin
  • Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
  • Zablocki Veterans Administration Medical Center — Milwaukee, Wisconsin
Phase 2 Recruiting Academic/Other

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where …

Sponsor: NRG Oncology
NCT ID: NCT05408845
Sites in Wisconsin:
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
  • Marshfield Medical Center - Minocqua — Minocqua, Wisconsin
  • ProHealth D N Greenwald Center — Mukwonago, Wisconsin
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Wisconsin:
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Wisconsin:
  • Froedtert & MCW Cancer Center — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Academic/Other

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to s…

Sponsor: Manish Patel
NCT ID: NCT03942653
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Industry

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…

Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Academic/Other

HEARTS Trial for Thoracic Cancers

The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic reg…

Sponsor: University of Wisconsin, Madison
NCT ID: NCT07132918
Sites in Wisconsin:
  • University of Wisconsin - Madison — Madison, Wisconsin
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Wisconsin:
  • Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Northwest Wisconsin Cancer Center — Ashland, Wisconsin
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Wisconsin:
  • Massive Bio SYNERGY-AI site — Milwaukee, Wisconsin
NA Recruiting Academic/Other

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical act…

Sponsor: Medical College of Wisconsin
NCT ID: NCT07227077
Sites in Wisconsin:
  • Froedtert Hospital — Milwaukee, Wisconsin

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07